Literature DB >> 32628293

Behavioural activation therapy for depression in adults.

Eleonora Uphoff1,2, David Ekers3,4, Lindsay Robertson1,2, Sarah Dawson1,5, Emily Sanger1, Emily South2, Zainab Samaan6, David Richards7, Nicholas Meader2, Rachel Churchill1,2.   

Abstract

BACKGROUND: Behavioural activation is a brief psychotherapeutic approach that seeks to change the way a person interacts with their environment. Behavioural activation is increasingly receiving attention as a potentially cost-effective intervention for depression, which may require less resources and may be easier to deliver and implement than other types of psychotherapy.
OBJECTIVES: To examine the effects of behavioural activation compared with other psychological therapies for depression in adults. To examine the effects of behavioural activation compared with medication for depression in adults. To examine the effects of behavioural activation compared with treatment as usual/waiting list/placebo no treatment for depression in adults. SEARCH
METHODS: We searched CCMD-CTR (all available years), CENTRAL (current issue), Ovid MEDLINE (1946 onwards), Ovid EMBASE (1980 onwards), and Ovid PsycINFO (1806 onwards) on the 17 January 2020 to identify randomised controlled trials (RCTs) of 'behavioural activation', or the main elements of behavioural activation for depression in participants with clinically diagnosed depression or subthreshold depression. We did not apply any restrictions on date, language or publication status to the searches. We searched international trials registries via the World Health Organization's trials portal (ICTRP) and ClinicalTrials.gov to identify unpublished or ongoing trials. SELECTION CRITERIA: We included randomised controlled trials (RCTs) of behavioural activation for the treatment of depression or symptoms of depression in adults aged 18 or over. We excluded RCTs conducted in inpatient settings and with trial participants selected because of a physical comorbidity. Studies were included regardless of reported outcomes. DATA COLLECTION AND ANALYSIS: Two review authors independently screened all titles/abstracts and full-text manuscripts for inclusion. Data extraction and 'Risk of bias' assessments were also performed by two review authors in duplicate. Where necessary, we contacted study authors for more information. MAIN
RESULTS: Fifty-three studies with 5495 participants were included; 51 parallel group RCTs and two cluster-RCTs. We found moderate-certainty evidence that behavioural activation had greater short-term efficacy than treatment as usual (risk ratio (RR) 1.40, 95% confidence interval (CI) 1.10 to 1.78; 7 RCTs, 1533 participants), although this difference was no longer evident in sensitivity analyses using a worst-case or intention-to-treat scenario. Compared with waiting list, behavioural activation may be more effective, but there were fewer data in this comparison and evidence was of low certainty (RR 2.14, 95% CI 0.90 to 5.09; 1 RCT, 26 participants). No evidence on treatment efficacy was available for behavioural activation versus placebo and behavioural activation versus no treatment. We found moderate-certainty evidence suggesting no evidence of a difference in short-term treatment efficacy between behavioural activation and CBT (RR 0.99, 95% CI 0.92 to 1.07; 5 RCTs, 601 participants). Fewer data were available for other comparators. No evidence of a difference in short term-efficacy was found between behavioural activation and third-wave CBT (RR 1.10, 95% CI 0.91 to 1.33; 2 RCTs, 98 participants; low certainty), and psychodynamic therapy (RR 1.21, 95% CI 0.74 to 1.99; 1 RCT,60 participants; very low certainty). Behavioural activation was more effective than humanistic therapy (RR 1.84, 95% CI 1.15 to 2.95; 2 RCTs, 46 participants; low certainty) and medication (RR 1.77, 95% CI 1.14 to 2.76; 1 RCT; 141 participants; moderate certainty), but both of these results were based on a small number of trials and participants. No evidence on treatment efficacy was available for comparisons between behavioural activation versus interpersonal, cognitive analytic, and integrative therapies. There was moderate-certainty evidence that behavioural activation might have lower treatment acceptability (based on dropout rate) than treatment as usual in the short term, although the data did not confirm a difference and results lacked precision (RR 1.64, 95% CI 0.81 to 3.31; 14 RCTs, 2518 participants). Moderate-certainty evidence did not suggest any difference in short-term acceptability between behavioural activation and waiting list (RR 1.17, 95% CI 0.70 to 1.93; 8 RCTs. 359 participants), no treatment (RR 0.97, 95% CI 0.45 to 2.09; 3 RCTs, 187 participants), medication (RR 0.52, 95% CI 0.23 to 1.16; 2 RCTs, 243 participants), or placebo (RR 0.72, 95% CI 0.31 to 1.67; 1 RCT; 96 participants; low-certainty evidence). No evidence on treatment acceptability was available comparing behavioural activation versus psychodynamic therapy. Low-certainty evidence did not show a difference in short-term treatment acceptability (dropout rate) between behavioural activation and CBT (RR 1.03, 95% CI 0.85 to 1.25; 12 RCTs, 1195 participants), third-wave CBT (RR 0.84, 95% CI 0.33 to 2.10; 3 RCTs, 147 participants); humanistic therapy (RR 1.06, 95% CI 0.20 to 5.55; 2 RCTs, 96 participants) (very low certainty), and interpersonal, cognitive analytic, and integrative therapy (RR 0.84, 95% CI 0.32 to 2.20; 4 RCTs, 123 participants). Results from medium- and long-term primary outcomes, secondary outcomes, subgroup analyses, and sensitivity analyses are summarised in the text. AUTHORS'
CONCLUSIONS: This systematic review suggests that behavioural activation may be more effective than humanistic therapy, medication, and treatment as usual, and that it may be no less effective than CBT, psychodynamic therapy, or being placed on a waiting list. However, our confidence in these findings is limited due to concerns about the certainty of the evidence. We found no evidence of a difference in short-term treatment acceptability (based on dropouts) between behavioural activation and most comparison groups (CBT, humanistic therapy, waiting list, placebo, medication, no treatment or treatment as usual). Again, our confidence in all these findings is limited due to concerns about the certainty of the evidence. No data were available about the efficacy of behaioural activation compared with placebo, or about treatment acceptability comparing behavioural activation and psychodynamic therapy, interpersonal, cognitive analytic and integrative therapies. The evidence could be strengthened by better reporting and better quality RCTs of behavioural activation and by assessing working mechanisms of behavioural activation.
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32628293      PMCID: PMC7390059          DOI: 10.1002/14651858.CD013305.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  124 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  Evaluation in a community mental health center: Huntsville, Alabama.

Authors:  D C Bolin; L Kivens
Journal:  Evaluation       Date:  1974

3.  Authors' reply.

Authors:  Latif Moradveisi; Marcus J H Huibers; Fritz Renner; Modabber Arasteh; Arnoud Arntz
Journal:  Br J Psychiatry       Date:  2013-06       Impact factor: 9.319

4.  Clinical depression: comparative efficacy of outpatient treatments.

Authors:  P D McLean; A R Hakstian
Journal:  J Consult Clin Psychol       Date:  1979-10

5.  Analysis of the components of a cognitive-behavioral intervention administered via conference call for preventing depression among non-professional caregivers: a pilot study.

Authors:  Fernando L Vázquez; Ángela Torres; Patricia Otero; Vanessa Blanco; Olga Díaz; Luis E Estévez
Journal:  Aging Ment Health       Date:  2016-05-17       Impact factor: 3.658

6.  Efficacy of a self-control therapy program in a psychiatric day-treatment center.

Authors:  J H van den Hout; A Arntz; F H Kunkels
Journal:  Acta Psychiatr Scand       Date:  1995-07       Impact factor: 6.392

7.  Behavioural activation therapy for depression in adults with non-communicable diseases.

Authors:  Eleonora Uphoff; Malini Pires; Corrado Barbui; Deepa Barua; Rachel Churchill; Doriana Cristofalo; David Ekers; Edward Fottrell; Papiya Mazumdar; Marianna Purgato; Rusham Rana; Judy Wright; Najma Siddiqi
Journal:  Cochrane Database Syst Rev       Date:  2020-08-06

8.  Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a qualitative process evaluation.

Authors:  Katie Finning; David A Richards; Lucy Moore; David Ekers; Dean McMillan; Paul A Farrand; Heather A O'Mahen; Edward R Watkins; Kim A Wright; Emily Fletcher; Shelley Rhodes; Rebecca Woodhouse; Faye Wray
Journal:  BMJ Open       Date:  2017-04-13       Impact factor: 2.692

9.  Behavioural activation for depression; an update of meta-analysis of effectiveness and sub group analysis.

Authors:  David Ekers; Lisa Webster; Annemieke Van Straten; Pim Cuijpers; David Richards; Simon Gilbody
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240

10.  Enduring effects of a 5-week behavioral activation program for subthreshold depression among late adolescents: an exploratory randomized controlled trial.

Authors:  Koki Takagaki; Yasumasa Okamoto; Ran Jinnin; Asako Mori; Yoshiko Nishiyama; Takanao Yamamura; Satoshi Yokoyama; Syouichi Shiota; Yuri Okamoto; Yoshie Miyake; Akiko Ogata; Yoshihiko Kunisato; Haruki Shimoda; Norito Kawakami; Toshi A Furukawa; Shigeto Yamawaki
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-09       Impact factor: 2.570

View more
  11 in total

1.  Patterns and predictors of high-intensity drinking and implications for intervention.

Authors:  Megan E Patrick; Yvonne M Terry-McElrath; Erin E Bonar
Journal:  Psychol Addict Behav       Date:  2021-05-24

Review 2.  Psychological treatments for depression and anxiety in dementia and mild cognitive impairment.

Authors:  Vasiliki Orgeta; Phuong Leung; Rafael Del-Pino-Casado; Afifa Qazi; Martin Orrell; Aimee E Spector; Abigail M Methley
Journal:  Cochrane Database Syst Rev       Date:  2022-04-25

3.  Improvements for Therapeutic Intervention from the Use of Web Applications and Machine Learning Techniques in Different Affectations in Children Aged 0-6 Years.

Authors:  María Consuelo Sáiz-Manzanares; Raúl Marticorena-Sánchez; Álvar Arnaiz-González
Journal:  Int J Environ Res Public Health       Date:  2022-05-27       Impact factor: 4.614

4.  Behavioural activation therapy for depression in adults with non-communicable diseases.

Authors:  Eleonora Uphoff; Malini Pires; Corrado Barbui; Deepa Barua; Rachel Churchill; Doriana Cristofalo; David Ekers; Edward Fottrell; Papiya Mazumdar; Marianna Purgato; Rusham Rana; Judy Wright; Najma Siddiqi
Journal:  Cochrane Database Syst Rev       Date:  2020-08-06

5.  Behavioural activation therapy for depression in adults.

Authors:  Eleonora Uphoff; David Ekers; Lindsay Robertson; Sarah Dawson; Emily Sanger; Emily South; Zainab Samaan; David Richards; Nicholas Meader; Rachel Churchill
Journal:  Cochrane Database Syst Rev       Date:  2020-07-06

6.  Effectiveness of a web-based behavioural activation intervention for individuals with depression based on the Health Action Process Approach: protocol for a randomised controlled trial with a 6-month follow-up.

Authors:  Lena Violetta Krämer; Claudia Mueller-Weinitschke; Tina Zeiss; Harald Baumeister; David Daniel Ebert; Jürgen Bengel
Journal:  BMJ Open       Date:  2022-01-24       Impact factor: 2.692

7.  An evaluation of a combined psychological and parenting intervention for HIV-positive women depressed in the perinatal period, to enhance child development and reduce maternal depression: study protocol for the Insika Yomama cluster randomised controlled trial.

Authors:  Tamsen J Rochat; Samukelisiwe Dube; Kobus Herbst; Cecilia A Hoegfeldt; Stephanie Redinger; Thandeka Khoza; Ruth Margret Bland; Linda Richter; Louise Linsell; Chris Desmond; Aisha K Yousafzai; Michelle Craske; Ed Juszczak; Melanie Abas; Taygen Edwards; David Ekers; Alan Stein
Journal:  Trials       Date:  2021-12-13       Impact factor: 2.279

8.  A Data-Driven Clustering Method for Discovering Profiles in the Dynamics of Major Depressive Disorder Using a Smartphone-Based Ecological Momentary Assessment of Mood.

Authors:  Claire R van Genugten; Josien Schuurmans; Adriaan W Hoogendoorn; Ricardo Araya; Gerhard Andersson; Rosa M Baños; Thomas Berger; Cristina Botella; Arlinda Cerga Pashoja; Roman Cieslak; David D Ebert; Azucena García-Palacios; Jean-Baptiste Hazo; Rocío Herrero; Jérôme Holtzmann; Lise Kemmeren; Annet Kleiboer; Tobias Krieger; Anna Rogala; Ingrid Titzler; Naira Topooco; Johannes H Smit; Heleen Riper
Journal:  Front Psychiatry       Date:  2022-03-17       Impact factor: 4.157

9.  Efficacy and moderators of cognitive therapy versus behavioural activation for adults with depression: study protocol of a systematic review and meta-analysis of individual participant data.

Authors:  Ellen Driessen; Zachary D Cohen; Lorenzo Lorenzo-Luaces; Steven D Hollon; David A Richards; Keith S Dobson; Sona Dimidjian; Jaime Delgadillo; Fernando L Vázquez; Kathleen McNamara; John J Horan; Pauline Gardner; Tian P Oei; Anuj H P Mehta; Jos W R Twisk; Ioana A Cristea; Pim Cuijpers
Journal:  BJPsych Open       Date:  2022-08-10

10.  Examining the Theoretical Framework of Behavioral Activation for Major Depressive Disorder: Smartphone-Based Ecological Momentary Assessment Study.

Authors:  Claire Rosalie van Genugten; Josien Schuurmans; Adriaan W Hoogendoorn; Ricardo Araya; Gerhard Andersson; Rosa Baños; Cristina Botella; Arlinda Cerga Pashoja; Roman Cieslak; David Daniel Ebert; Azucena García-Palacios; Jean-Baptiste Hazo; Rocío Herrero; Jérôme Holtzmann; Lise Kemmeren; Annet Kleiboer; Tobias Krieger; Ewelina Smoktunowicz; Ingrid Titzler; Naira Topooco; Antoine Urech; Johannes H Smit; Heleen Riper
Journal:  JMIR Ment Health       Date:  2021-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.